Cyclin E (CCNE1) activators play a pivotal role in orchestrating the finely tuned symphony of cell cycle progression. This diverse array of compounds, carefully selected for their strategic impact, modulates the functional activity of cyclin E through a range of direct and indirect mechanisms. The regulation of cyclin E is an intricate dance, and these activators act as choreographers, delicately influencing specific signaling pathways and biological processes that are intimately associated with the protein. At the forefront of cyclin E modulation are agonists, compounds that actively enhance the stability of cyclin E and promote its pivotal role in cell cycle transitions. These agonists work in concert with the natural progression of the cell cycle, ensuring that cyclin E is available at the right time and in the right amount to facilitate the orderly passage through cell cycle checkpoints. The nuanced interplay between cyclin E and its agonists sheds light on the dynamic regulation of cell division, providing researchers with valuable insights into the molecular intricacies that govern this fundamental biological process.
In contrast, antagonists of cyclin E bring a different set of dynamics to the stage. These compounds act as disruptors, hindering the activity of cyclin E and introducing a level of control to prevent unscheduled cell cycle progression. By inhibiting cyclin E, antagonists serve as checkpoints, ensuring that cells undergo proper regulatory scrutiny before advancing to the next phase of the cell cycle. This regulatory function is crucial for maintaining genomic integrity and preventing aberrant cell division. Further enriching the toolkit of cyclin E modulation are modulators, compounds that fine-tune intracellular signaling pathways associated with cyclin E. These modulators contribute to the precision of cell cycle regulation, adjusting the tempo and ensuring that the intricate balance of cyclin E activity aligns with the broader cellular context. The interplay between cyclin E and its modulators provides an additional layer of complexity to our understanding of cell cycle dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, a cyclin-dependent kinase inhibitor, directly inhibits CDK2, thereby enhancing cyclin E activity by preventing its degradation and promoting G1 to S phase transition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol acts as a broad-spectrum cyclin-dependent kinase inhibitor, suppressing multiple CDKs, including CDK2 involved in cyclin E regulation, thereby enhancing cyclin E function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly impacts cyclin E function by disrupting the mTOR pathway, leading to cell cycle arrest and reduced cyclin E-dependent cell cycle progression. | ||||||
SB 218078 | 135897-06-2 | sc-203692 | 1 mg | $136.00 | 1 | |
SB-218078, a specific CDK2 inhibitor, directly impedes CDK2-cyclin E complex formation, enhancing cyclin E stability and activity during the cell cycle. | ||||||
NU6027 | 220036-08-8 | sc-215591 | 10 mg | $156.00 | 1 | |
NU6027, a selective CDK2 inhibitor, promotes the stabilization of cyclin E, facilitating its role in regulating the G1 to S phase transition. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-oxime targets CDK2, contributing to the sustained activity of cyclin E and promoting proper cell cycle progression. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A, a CDK inhibitor, directly impacts cyclin E by inhibiting CDK2 activity, thereby promoting the proper progression of the cell cycle. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
LY2835219, a selective CDK4/6 inhibitor, indirectly affects cyclin E activity by preventing the formation of CDK4/6-cyclin D complexes, leading to enhanced cyclin E-dependent cell cycle progression. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438, a potent inhibitor of CDK1, CDK2, and CDK9, directly enhances cyclin E function by inhibiting CDK2 activity and promoting proper cell cycle advancement. | ||||||